:Cimemoxin
{{Short description|Chemical compound}}
{{Drugbox
| IUPAC_name = cyclohexylmethylhydrazine
| image = Cimemoxin.svg
| image_class = skin-invert-image
| CAS_number = 3788-16-7
| CAS_number_Ref = {{cascite|correct|CAS}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 584QS921R2
| CAS_supplemental =
| ATC_prefix = None
| ATC_suffix =
| PubChem = 71824
| ChEMBL = 2106052
| ChemSpiderID = 64848
| C=7 | H=16 | N=2
| smiles = NNCC1CCCCC1
| StdInChI = 1S/C7H16N2/c8-9-6-7-4-2-1-3-5-7/h7,9H,1-6,8H2
| StdInChIKey = BDHMBGHSWFWYSP-UHFFFAOYSA-N
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_category =
| legal_status =
| routes_of_administration =
}}
Cimemoxin (INN), or cyclohexylmethylhydrazine, is a hydrazine monoamine oxidase inhibitor (MAOI) antidepressant which was never marketed.{{cite web | url =https://www.who.int/medicines/services/inn/StemBook_2011_Final.pdf | author = World Health Organization | title = The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances | year = 2011 | accessdate = 2012-05-20}}
Synthesis
It possesses 50 times the relative activity of iproniazid and 25x nialamide (see patent).
3-Cyclohexene-1-carbaldehyde [100-50-5] (aka 1,2,3,6-Tetrahydrobenzaldehyde) is reacted with N-acetylhydrazine to give the hydrazone, which is reduced by catalytic hydrogenation. The acetyl group is removed by acid hydrolysis.
See also
References
{{Reflist}}
{{Antidepressants}}
{{Navboxes
| title = Monoaminergics
| state = collapsed
| list1 = {{Adrenergics}} {{Dopaminergics}} {{Melatonergics}} {{Serotonergics}}
}}
Category:Monoamine oxidase inhibitors
{{nervous-system-drug-stub}}